Compare Serum Klotho Levels in Patients on Oral Antidiabetic Treatment

Serum Klotho Level in Patients on Oral Antidiabetic Treatment

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03585777

Enrollment

Registered

2018-07-13

Start date

2018-10-11

Completion date

2019-03-31

Last updated

2018-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Compare Serum Level of Klotho in Patients on Oral Antidiabetic Treatment

Brief summary

Klotho is a protein found in serum, kidney,heart,brain and in other tissues,it has many functions,it is viewed as the anti aging hormone. Aging kidneys are characterized by progressive scarring and measurable declines in renal function

Detailed description

Objectives To study serum klotho level among diabetic patients attending diabetes and endocrine clinic in Fayoum university on oral antidiabetic treatment Study Design: This study will be an observational prospective cohort study. The study duration will be 2 months. Study Methods: * Population of Study * Group 1 :compare serum klotho levels in patients taking glimeperirde versus levels in patients taking metformin * Group 2 : compare serum klotho levels in patients taking glimeperirde versus levels in patients taking linagliptin * Group 3 : compare serum klotho levels in patients taking glimeperirde versus levels in patients taking impaglifluzin * Inclusion Criteria : * Group 1 :Diabetics candidate for oral treatment * Group 2 :Diabetics candidate for oral treatment * Group 3 :Diabetics candidate for oral treatment * Exclusion Criteria : Diabetics candidate for insulin treatment There will be three arms to this study; the first arm will enroll patients on glimepiride and patients on metformin to compare serum klotho levels. The second arm will enroll patients on glimepiride and patients on linagliptin to compare serum klotho levels. The third arm will enroll patients on glimepiride and patients on impaglifluzin to compare serum klotho levels Each arm will enroll 40 patients, 20 patients on glimiperide treatment,20 patient will on the other drug,patients will be selected from Fayoum university diabetes and endocrine clinic Data collection: Patients will be subjected to; full clinical examination,waist hip ratio assessment,BMI assessment fasting blood glucose,2PP blood glucose,HbA1C, urea, creatinine, uric acid total calcium,albumin, phospherus, estimated GFR, ACR, total cholesterol, triglycerides, serum klotho, FGF 23 levels assessment , also fracrtional excretion of phospherus will be assessed. Control of blood glucose will be done along the period of the study. At the end of the 2 months,reassessment of the above mentioned parameters will be done.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diabetics candidate for oral treatment

Exclusion criteria

* Diabetics candidate for insulin treatment

Design outcomes

Primary

Measure	Time frame	Description
Beneficial effect manifested by a statistical significant decrease in klotho levels	2 months	An anticipated statistical significant decrease in klotho level

Secondary

Measure	Time frame	Description
No beneficial effect manifested by by a non significant decrease in klotho level or a rise in the level	2 months	Non statistical significant decrease in klotho level, or a significant rise in it

Countries

Egypt

Contacts

Primary ContactAhmed Hammad, MD

aah12@fayoum.edu.eg00201001574639

Backup ContactMohammed Mashaheet, MD

mam22@fayoum.edu.eg00201227904660

Outcome results